Since MAGE-A4 exhibits a relatively high frequency of expression, and appears to direct a major pattern of co-expression of other MAGE antigens (Fig. 2b), we also propose MAGE-A4 as a priority target for ovarian cancer immunotherapy. Here, MAGEA4 is linked to ovarian cancer.